Natriuretic peptides suffer from rapid proteolytic degradation and fast renal clearance. Grafting these peptides onto antibody scaffolds prevents premature metabolic breakdown and extends therapeutic circulation time.

Primary oncogenic drivers frequently develop mutations or bypass signaling pathways that render single-agent therapies ineffective. Targeting these escape mechanisms restores therapeutic sensitivity and prevents clinical relapse.

Low patient response rates and immune evasion limit the efficacy of monotherapies. Synergistic combinations and optimized dosing overcome immunosuppressive barriers to improve clinical outcomes.

Low binding affinity and rapid clearance of monomeric ligands limit diagnostic sensitivity and therapeutic efficacy. Multimeric chelating structures increase avidity and retention at target sites to overcome poor signal-to-noise ratios.